275 related articles for article (PubMed ID: 26422291)
1. Somatic p.T771R KDR (VEGFR2) Mutation Arising in a Sporadic Angioma During Ramucirumab Therapy.
Lim YH; Odell ID; Ko CJ; Choate KA
JAMA Dermatol; 2015 Nov; 151(11):1240-3. PubMed ID: 26422291
[TBL] [Abstract][Full Text] [Related]
2. The safety and efficacy of ramucirumab for the treatment of metastatic colorectal cancer.
Diaz-Serrano A; Riesco-Martinez MC; Garcia-Carbonero R
Expert Rev Anticancer Ther; 2016 Jun; 16(6):585-95. PubMed ID: 27144874
[TBL] [Abstract][Full Text] [Related]
3. Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab.
Arnold D; Fuchs CS; Tabernero J; Ohtsu A; Zhu AX; Garon EB; Mackey JR; Paz-Ares L; Baron AD; Okusaka T; Yoshino T; Yoon HH; Das M; Ferry D; Zhang Y; Lin Y; Binder P; Sashegyi A; Chau I
Ann Oncol; 2017 Dec; 28(12):2932-2942. PubMed ID: 28950290
[TBL] [Abstract][Full Text] [Related]
4. The safety of ramucirumab for the treatment of colorectal cancer.
Noguerido A; Mulet-Margalef N; Matos I; Ros J; Argilés G; Élez E; Tabernero J
Expert Opin Drug Saf; 2018 Sep; 17(9):945-951. PubMed ID: 30073902
[TBL] [Abstract][Full Text] [Related]
5. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.
Tabernero J; Yoshino T; Cohn AL; Obermannova R; Bodoky G; Garcia-Carbonero R; Ciuleanu TE; Portnoy DC; Van Cutsem E; Grothey A; Prausová J; Garcia-Alfonso P; Yamazaki K; Clingan PR; Lonardi S; Kim TW; Simms L; Chang SC; Nasroulah F;
Lancet Oncol; 2015 May; 16(5):499-508. PubMed ID: 25877855
[TBL] [Abstract][Full Text] [Related]
6. Ramucirumab: a novel antiangiogenic agent.
Wadhwa R; Taketa T; Sudo K; Blum-Murphy M; Ajani JA
Future Oncol; 2013 Jun; 9(6):789-95. PubMed ID: 23718298
[TBL] [Abstract][Full Text] [Related]
7. Exome Sequencing of Plasma DNA Portrays the Mutation Landscape of Colorectal Cancer and Discovers Mutated VEGFR2 Receptors as Modulators of Antiangiogenic Therapies.
Toledo RA; Garralda E; Mitsi M; Pons T; Monsech J; Vega E; Otero Á; Albarran MI; Baños N; Durán Y; Bonilla V; Sarno F; Camacho-Artacho M; Sanchez-Perez T; Perea S; Álvarez R; De Martino A; Lietha D; Blanco-Aparicio C; Cubillo A; Domínguez O; Martínez-Torrecuadrada JL; Hidalgo M
Clin Cancer Res; 2018 Aug; 24(15):3550-3559. PubMed ID: 29588308
[No Abstract] [Full Text] [Related]
8. Ramucirumab: targeting angiogenesis in the treatment of gastric cancer.
Smyth EC; Tarazona N; Chau I
Immunotherapy; 2014; 6(11):1177-86. PubMed ID: 25496333
[TBL] [Abstract][Full Text] [Related]
9. Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer.
Doebele RC; Spigel D; Tehfe M; Thomas S; Reck M; Verma S; Eakle J; Bustin F; Goldschmidt J; Cao D; Alexandris E; Yurasov S; Camidge DR; Bonomi P
Cancer; 2015 Mar; 121(6):883-92. PubMed ID: 25377507
[TBL] [Abstract][Full Text] [Related]
10. Efficient and safe application of a FOLFIRI/bevacizumab combination to a patient with locally advanced rectal cancer and severe chronic renal failure.
Cicin I; Karagol H; Uzunoglu S; Uygun K
Onkologie; 2007 Feb; 30(1-2):65. PubMed ID: 17264528
[No Abstract] [Full Text] [Related]
11. [Nephrotic Syndrome Induced by Ramucirumab for Metastatic Rectal Cancer].
Sakabe R; Shirakawa K; Yoshimura K; Otsuka H; Kuwada A; Tahara K; Hotei H; Maeda Y
Gan To Kagaku Ryoho; 2018 Aug; 45(8):1205-1207. PubMed ID: 30158421
[TBL] [Abstract][Full Text] [Related]
12. Synergy between cetuximab and chemotherapy in tumors of the gastrointestinal tract.
Mahtani RL; Macdonald JS
Oncologist; 2008 Jan; 13(1):39-50. PubMed ID: 18245011
[TBL] [Abstract][Full Text] [Related]
13. Primary results of ROSE/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer.
Mackey JR; Ramos-Vazquez M; Lipatov O; McCarthy N; Krasnozhon D; Semiglazov V; Manikhas A; Gelmon KA; Konecny GE; Webster M; Hegg R; Verma S; Gorbunova V; Abi Gerges D; Thireau F; Fung H; Simms L; Buyse M; Ibrahim A; Martin M
J Clin Oncol; 2015 Jan; 33(2):141-8. PubMed ID: 25185099
[TBL] [Abstract][Full Text] [Related]
14. Risk of hypertension with ramucirumab-based therapy in solid tumors: data from a literature based meta-analysis.
Roviello G; Pacifico C; Corona P; Generali D
Invest New Drugs; 2017 Aug; 35(4):518-523. PubMed ID: 28285368
[TBL] [Abstract][Full Text] [Related]
15. Anti-angiogenic agent ramucirumab: meaningful or marginal?
Wadhwa R; Elimova E; Shiozaki H; Sudo K; Blum MA; Estrella JS; Chen Q; Song S; Ajani JA
Expert Rev Anticancer Ther; 2014 Apr; 14(4):367-79. PubMed ID: 24605771
[TBL] [Abstract][Full Text] [Related]
16. Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: results of a Phase II MARGIT trial.
Horisberger K; Treschl A; Mai S; Barreto-Miranda M; Kienle P; Ströbel P; Erben P; Woernle C; Dinter D; Kähler G; Hochhaus A; Post S; Willeke F; Wenz F; Hofheinz RD;
Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1487-93. PubMed ID: 19131187
[TBL] [Abstract][Full Text] [Related]
17. Cetuximab and chemoradiation for rectal cancer--is the water getting muddy?
Glynne-Jones R; Mawdsley S; Harrison M
Acta Oncol; 2010 Apr; 49(3):278-86. PubMed ID: 20180626
[TBL] [Abstract][Full Text] [Related]
18. KRAS mutation status and clinical outcome of preoperative chemoradiation with cetuximab in locally advanced rectal cancer: a pooled analysis of 2 phase II trials.
Kim SY; Shim EK; Yeo HY; Baek JY; Hong YS; Kim DY; Kim TW; Kim JH; Im SA; Jung KH; Chang HJ
Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):201-7. PubMed ID: 22672749
[TBL] [Abstract][Full Text] [Related]
19. A critical review on ramucirumab in the treatment of advanced urothelial cancer.
Vlachostergios PJ; Lee A; Thomas C; Walsh R; Tagawa ST
Future Oncol; 2018 May; 14(11):1049-1061. PubMed ID: 29231057
[TBL] [Abstract][Full Text] [Related]
20. Eruptive cherry angiomas developing in a patient treated with ramucirumab.
Espinosa Lara P; Medina-Puente C; Riquelme Oliveira A; Jiménez-Reyes J
Acta Oncol; 2018 May; 57(5):709-711. PubMed ID: 29188737
[No Abstract] [Full Text] [Related]
[Next] [New Search]